Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Gyoergy Ruzsics

Jozsef Barkoczy

Kalman Nagy

Balazs Volk

Gyula Simig

Ferenc Lorant Bartha

Adrienn Keszthelyi

Gyoergyi Kovanyine Lax

Gabor Nemeth

Laszlo Pongo

Eva Sipos

Janos Imre

Andras Dancso

Judit Broda

Gyoergy Clementis

Imre Kiraly

Jozsef Debreczeni

Peter Slegel

Gyoergy Morovjan

Gyoergy Krasznai

Valeria Hoffmanne Fekete

Imre Koehegyi

Adrienn Karasz

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

Growing community of inventors

Hoegyesz, Hungary

Gyoergy Ruzsics